News

This is Calculus’ understanding of the budget. Tax treatment is subject to change and depends on individual circumstances.

The exit has delivered up to a 1.8x return for Calculus investors. For the Calculus VCT, it generates an additional £1.53 million in cash for the portfolio.

Harrogate and London-based Grateful – the automated tip pooling and tronc platform – has raised £1.5 million ($2m) seed funding from Calculus Capital.

Calculus invests as part of a £70million Series A financing to drive clinical development of therapies for hard to treat cancers.

Arecor partners with Sequel Med Tech on AT278 insulin and raises up to $11m from Ligand, accelerating Phase 2 readiness, extending cash runway to 2027, and positioning for next-generation diabetes care and significant shareholder value creation.

Calculus portfolio company C4X Discovery selects a best-in-class oral IBD candidate, highlighting innovation and value creation in UK biotech.

Here we speak to Richard Moore, Co-Head of Investments, on the key lessons learned and how that informs our investment strategy in the technology space.